HIV Infections Clinical Trial
Official title:
28 Day Protocol for the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)
NCT number | NCT00002278 |
Other study ID # | 038B |
Secondary ID | JRD 64,433/1102 |
Status | Completed |
Phase | N/A |
First received | November 2, 1999 |
Last updated | June 23, 2005 |
To evaluate the safety and efficacy of diclazuril capsules as a treatment for cryptosporidial related diarrhea in AIDS patients who have been treated in the double-blind study # JRD 64,433/1101 and have relapsed, or de-novo patients who have been diagnosed with cryptosporidial related diarrhea and who meet the inclusion and exclusion criteria of this protocol.
Status | Completed |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 12 Years to 65 Years |
Eligibility |
Inclusion Criteria Concurrent Medication: Allowed: - Zidovudine (AZT). - Didanosine (ddI) allowed but discouraged, must have been stabilized on a constant dose for 3 weeks or more. - Aerosolized pentamidine. - Nystatin for control of oropharyngeal infections. Nystatin must not be taken within two hours of diclazuril. - Ganciclovir therapy only for CMV retinitis is permitted if the patient has been treated for at least 4 weeks prior to study entry and is stable on the drug. - Loperamide may be taken if patient has been on long term loperamide prior to study entry but should not be started during the course of this protocol. Patients must have the following: Written informed consent given after the purpose and nature of the study, as well as the possible adverse effects related to the study drug, have been explained. - Be willing and able to return for all subsequent weekly visits and the two week visit post completion of therapy (follow-up). Prior Medication: Allowed: - Diclazuril. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Uncontrolled vomiting. - Estimated survival less than 28 days. - Other treatable enteric pathogens must be treated and eradicated prior to study entry. Concurrent Medication: Excluded: - Amphotericin B. - Other antibiotics or antiprotozoal drugs. - Other investigational agents. - Trimethoprim/sulfamethoxazole. - Antifungal medications except nystatin. - Ganciclovir for other than Cytomegalovirus (CMV) retinitis. - Antidiarrheal agents other than patients on long term loperamide prior to study entry. Patients with the following are excluded: - Undependable in following the instructions of the investigator. - Not able to swallow capsules. - Uncontrolled vomiting. - Estimated survival less than 28 days. Prior Medication: Excluded: - Diclazuril within 2 weeks of study entry. |
Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Bellevue Hosp / New York Univ Med Ctr | New York | New York |
United States | Cornell Univ Med Ctr | New York | New York |
United States | Saint Luke's - Roosevelt Hosp Ctr | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Janssen, LP |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |